Search

Displaying results 5231 - 5240 of 5264 in total
  1. Drug

    Sodium molybdate

    go.drugbank.com/drugs/DB14496
    Approved

    Mixtures: Addamel N, ADDAMEL N
  2. Drug

    Ferrous cation

    go.drugbank.com/drugs/DB14510
    Investigational

    Products: RULOFER N, CROM
  3. Drug

    Fluocortolone

    go.drugbank.com/drugs/DB08971
    ApprovedWithdrawn

    Fluocortolone is a glucocorticoid with anti-inflammatory activity used topically for various skin disorders.

    Mixtures: SCHERIPROCT N CREAM
  4. Drug

    Chlorine dioxide

    go.drugbank.com/drugs/DB12453
    Approved

    Chlorine Dioxide has been used in trials studying the treatment of Halitosis.

    Products: Skin N Clean
  5. Drug

    Methyl pyrrolidone

    go.drugbank.com/drugs/DB12521
    Investigational

    N Methyl Pyrrolidone is under investigation for the treatment of Multiple Myeloma.

    Synonyms: N-methylpyrrolidone, N-methyl-pyrrolidone
  6. Drug

    N-sulfoglucosamine sulfohydrolase recombinant

    go.drugbank.com/drugs/DB12722
    Investigational

    N-sulfoglucosamine sulfohydrolase recombinant is under investigation for the treatment of Mucopolysaccharidosis III and Sanfilippo Syndrome Type A (MPS IIIA).

  7. Drug

    N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide

    go.drugbank.com/drugs/DB06944
    Experimental

    N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide is a solid. This compound belongs to the naphthalenes. … The proteins that N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide targets include cyclin-A2 and cyclin-dependent kinase 2.

    Synonyms: N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide
  8. Drug

    CPD 923

    go.drugbank.com/drugs/DB05856
    Experimental

    CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.

  9. Drug

    OSI-461

    go.drugbank.com/drugs/DB05415
    Investigational

    OSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).

  10. Drug

    GW 468816

    go.drugbank.com/drugs/DB05417
    Investigational

    GW 468816 is glycine receptor antagonist. It is designed to aid abstinence in people who have just quit smoking, delaying the time to relapse. It was undergoing phase II trials since December 2003.

    Categories: Receptors, N-Methyl-D-Aspartate, antagonists & inhibitors